Adherus™ Dural Sealant in Spinal Procedures

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

114 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-19

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test an experimental device, the Adherus AutoSpray and Adherus AutoSpray ET Dural Sealant, in spinal surgical procedures.

This study is being done to compare Adherus AutoSpray and Adherus AutoSpray ET Dural Sealant to DuraSeal Exact Spinal Sealant, which has already received Federal Food and Drug Administration (FDA) approval in spinal procedures.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Effectiveness of the Adherus Dural Sealant System When Used as a Dural Sealant in Cranial Procedures

NCT01158378

Elective Cranial Procedures With Dural Incision

COMPLETED PHASE3

Study to Evaluate Safety and Effectiveness of Spinal Sealant

NCT00594035

Spinal Procedure Requiring Dura Incision

COMPLETED NA

DuraSeal Exact Spine Sealant System Post-Approval Study

NCT01410864

Dural Sealing

COMPLETED

Use of Spinal Sealant System During Spinal Surgery

NCT00458354

Spine Surgery Excessive Repair Spinal Cord Injuries +1 more

COMPLETED PHASE3

Duraplasty for Acute Traumatic Spinal Cord Injury

NCT07280351

Spinal Cord Injury, Acute Spinal Cord Injury (SCI), Initial Encounter Spinal Cord Injury Cervical

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, randomized, controlled, single-blind, multicenter, pivotal trial that will evaluate the safety and effectiveness of Adherus Dural Sealant when used in conjunction with standard methods of dural repair in spinal procedures. This trial uses the commercially available DuraSeal Exact as an active control. The trial is designed to demonstrate non-inferiority of Adherus Dural Sealant to DuraSeal Exact.

Subjects who are undergoing spinal surgery, consent to participate in this trial and experience a durotomy will be considered for study enrollment. Following a two-tiered inclusion/exclusion consideration, subjects will be randomized intraoperatively using a 1:1 randomization ratio. Up to 90 subjects will be randomized to treatment with either Adherus Dural Sealant or DuraSeal Exact with at least 50% of subjects undergoing procedures at lumbar or lumbosacral levels. Up to 30 investigational sites within the United States will participate in this trial.

A primary composite endpoint evaluating safety and effectiveness will be measured within a 90-day required follow-up period post-procedure. Subjects will be followed at discharge or between postoperative days (POD) 1-4 from the index procedure (whichever occurs first) and at 30 days and 90 days post-index procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Duraplasty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adherus Dural Sealant System

Device: Adherus Dural Sealant, In situ polymerizing sealant

Group Type EXPERIMENTAL

Adherus Dural Sealant System

Intervention Type DEVICE

Adherus Dural Sealant, In situ polymerizing sealant

DuraSeal Exact Dural Sealant System

Device: DuraSeal Exact (P080013b)

Group Type ACTIVE_COMPARATOR

DuraSeal Exact Dural Sealant System

Intervention Type DEVICE

DuraSeal Exact (P080013b)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adherus Dural Sealant System

Adherus Dural Sealant, In situ polymerizing sealant

Intervention Type DEVICE

DuraSeal Exact Dural Sealant System

DuraSeal Exact (P080013b)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is ≥ 18 and ≤ 75 years old.
2. Subject is scheduled for an elective spinal procedure that will require a planned durotomy.
3. Subject requires a procedure involving a Class I/clean wound (uninfected surgical wound in which no inflammation is encountered).
4. Subject is able and willing to provide informed consent and HIPAA authorization.
5. Subject is able and willing to meet all study requirements, including attending all post-index procedure assessment visits and radiological tests.

6. Subject has durotomy edges that can be re-approximated using the investigator's standard methods of dural repair.

Exclusion Criteria

1. Subject has clinically significant hydrocephalus or clinical evidence of altered CSF dynamics.
2. Subject has a pre-existing external lumbar CSF drain or internal CSF shunt.
3. Subject has experienced previous CSF leak (secondary to trauma, neoplasm, surgery, or other etiology).
4. Subject is undergoing a Chiari malformation procedure.
5. Subject has undergone a previous spinal procedure in the same anatomical location.
6. Subject has had radiation treatment to the surgical site, or standard fractionated radiation therapy is planned within ten days post indexprocedure.
7. Subject has spinal metallic implants that may cause significant imaging artifact on the MRI evaluation of the spine.
8. Subject has metallic implant(s) that are not MRI compatible, e.g., cochlear implant, neurostimulator, stent, surgical clip, cardiac pacemakers, or other non-MRI compatible implants, or an elective implant of such devices is planned during the course of the study. Note: mercury amalgam dental fillings or similar metallic dental prostheses are not an exclusion criterion.
9. Subject has a known malignancy or another condition with anticipated survival shorter than six months.
10. Subject has undergone chemotherapy treatment, excluding hormonal therapy, within three weeks prior to the planned index procedure, or chemotherapy treatment is planned within two weeks after the index procedure is performed.
11. Subject has been treated with chronic steroid therapy (defined as regular (daily) administration of steroid agent(s) for ≥ 8 weeks) unless discontinued greater than four weeks prior to the planned index procedure. Note: standard acute perioperative steroids are permitted; administration of steroid agents for \< 8 weeks duration prior to the planned index procedure is permitted.
12. Subject has received warfarin, heparin, other anticoagulant agents, aspirin or non steroid anti-inflammatory agents on a daily basis and pre-surgical, standard of care drug wash-out did not occur.
13. Subject has a compromised immune system or autoimmune disease or is on chronic immunosuppressant agents at baseline.
14. Subject has a systemic infection or evidence of any infection near planned operative site.
15. Subject has a serum creatinine level \> 2.0 mg/dL.
16. Subject has a serum total bilirubin \> 2.5 mg/dL at baseline.
17. Subject has uncontrolled diabetes as evidenced by an HbA1c \> 7% prior to surgery.
18. Subject has a known allergy to FD\&C Blue #1 and/or FD\&C Yellow #5 or any of the constituents of the dural sealants.
19. Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study.
20. Subject is participating in a clinical trial of another investigational drug or device and has not completed the required follow-up period.

21. Subject has an incidental finding that meets any pre-operative exclusion criterion listed above.
22. Subject's dural defect cannot be closed with suture and/or duraplasty material.
23. Subject has a gap \> 2 mm present between dural edges, or between the edge of dura and duraplasty material, based on visual estimate by surgeon before application of the surgical sealant.
24. Subject had undergone laminoplasty decompression.
25. Subject had undergone a syringomyelia procedure where the shunt is not placed in the subarachnoid position.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No